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Improved stem cell-derived pancreatic islet (SC-islet) differentiation protocols robustly generate insulin-
secreting b cells from patient induced pluripotent stem cells (iPSCs). These advances are enabling in vitro
disease modeling studies and the development of an autologous diabetes cell replacement therapy. SC-islet
technology elucidates key features of human pancreas development and diabetes disease progression
through the generation of pancreatic progenitors, endocrine progenitors, and b cells derived from diabetic
and nondiabetic iPSCs. Combining disease modeling with gene editing and next-generation sequencing re-
veals the impact of diabetes-causing mutations and diabetic phenotypes on multiple islet cell types. In addi-
tion, the supply of SC-islets, containing b and other islet cell types, is unlimited, presenting an opportunity for
personalized medicine and overcoming several disadvantages posed by donor islets. This review highlights
relevant studies involving iPSC-b cells and progenitors, encompassing new conclusions involving cells from
patients with diabetes and the therapeutic potential of iPSC-b cells.
INTRODUCTION
Diabetes is a disease diagnosed in >451 million patients world-
wide.1 This epidemic is caused by the death and dysfunction
of pancreatic, insulin-secreting b cells. The current treatments
for patients with type 1 diabetes, constituting 10% of diabetes
mellitus diagnoses, include exogenous insulin injections and
cadaveric donor islet transplantation.2,3 Long-term exogenous
insulin is commonly accompanied by hyperglycemia and hypo-
glycemia events, which can cause cardiovascular and kidney
complications.4 A cell therapy pipeline developed from cadav-
eric islet transplantation emphasizes the potential power of cell
replacement technology to enhance the quality of life for patients
with diabetes. However, there is a limited supply of cadaveric
donors and a need for immunosuppression.5,6 An alternate
promising source for diabetes cell therapy is self-renewable hu-
man pluripotent stem cells (hPSCs).
Stem cell-derived definitive endoderm (DE), pancreatic pro-
genitors (PPs), and endocrine progenitors (EPs) were created
starting in 2006.7–9 These initial differentiation stages were
critical to create stem cell-derived b (SC-b) cells and continue
to be the initial stages in several differentiation protocols. SC-
b cells were first generated in 2014 from embryonic stem cells
(ESCs), with several key b cell characteristics capable of
reversing diabetes in mouse models several weeks after trans-
plantation.10,11 Recent advances in differentiation protocols
have enabled the robust generation of SC-b cells from patient
induced pluripotent stem cells (iPSCs).12–14 The new, refined
protocols generated cell populations commonly called SC-is-
lets due to the composition consisting of almost all endocrine
(chromogranin A+) cells, including glucagon+ alpha (SC-a) and
somatostatin+ delta (SC-d) cells. Patient-derived diabetic
iPSC-b cells allow for disease progression studies of pancre-
atic and EPs during stages 4 and 5 of differentiation,
benefiting many groups studying diabetes from patient stem
cells due to the unknown presence and progression of dia-
betes at early development stages. In addition, studying pa-
tient SC-b cells with a known diabetic genotype at the final
cell fate in stage 6 is effective for the diabetes field, drug
screening, and future therapeutics. Furthermore, disease
modeling with patient cells allows for a better understanding
of multiple forms of diabetes, such as type 1 (T1D), type 2
(T2D), cystic fibrosis-related diabetes (CFRD), and monoge-
netic diabetes (MD).3 Genetic engineering tools have been
applied to patient iPSC-islets to generate nondiabetic (ND)
phenotype and transgenic cell lines. Specifically, our group
and colleagues used gene editing to correct MD variants
found in neonatal diabetes (NeoD), maturity-onset diabetes
of the young (MODY), and Wolfram syndrome (WS).15–17 Re-
sults from these studies demonstrated the potential for an
autologous diabetes cell therapy. Microfluidic devices also
present an opportunity for improved culture systems and
drug screening platforms to study diabetes in vitro.18 Stem
cell technology holds immense potential as a cell therapy to
combat diabetes. This review summarizes the present litera-
ture on iPSC-islets from patients with diabetes by analyzing
diabetes modeling and cell therapy development to highlight
the potential of personalized therapy.
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GENERATION EFFICIENCY OF iPSC-ISLETS FROM
MULTIPLE DIFFERENTIATION PROTOCOLS
Differentiation protocols for SC-islets generally target the same
developmental stages, beginning with DE and primitive gut tube,
then narrowing cell fate to pancreatic and EPs, and ultimately tar-
geting the final differentiated b cell.7,8,10–14 Small molecules and
growth factors are typically used to navigate the pathwaysneeded
for the differentiation stages, aiming tomimic embryonic develop-
ment. b cell and progenitor stemcell differentiation protocols have
been meticulously developed over the past decade, beginning
with DE and leading to functional SC-b cells, which have been re-
viewed previously.19–23 Alternatively, Sui et al.24 used nuclear
transfer embryonic stem (NT-ES) cells to generate NT-ES-b cells.
Favorable off targets were commonly produced during the proto-
col, includinga and d cells. The presenceof allmain islet endocrine
cell types led the field to rename SC-b cell clusters to SC-is-
lets.17,25,26Enterochromaffin (SC-EC)cellswere recently identified
as an off target generated in SC-islet differentiations that persist
in vivo, validated bymultiple groups.25,26 SC-ECcells are an endo-
crine (CHGA+) cell type, and their effect on SC-islet function and
maturation is unknown.25 In addition, adverse off target cell types,
such as neural progenitor cells (NPCs), pancreatic exocrine
(mesenchyme, acinar), and polyhormonal (PH) cells, can contam-
inate the final cell cluster. Differentiation efficiency, genetic
background, and disease state of the hPSCs influenced the
composition proportions of these off targets.15,17,25
Before the recent b cell differentiation protocols, iPSCs were
unable to differentiate into SC-b cells as efficiently as ESCs. Pro-
tocols were typically optimized for a single ESC line, producing
iPSC-b cells at lower efficiencies.10,11,14 SC-b or SC-b-like cells
ranged from 17%27 to 73%14 C-Peptide+, a proxy marker for in-
sulin, at the final stage of differentiation. Of note, C-Peptide+
cells can include both functional (NKX6.1+C-Peptide+) cells
and PH (GCG+C-Peptide+ and SST+C-Peptide+) cells, which
are nonfunctional and immature endocrine cells. Protocols with
smaller cell yields used GFP reporter cell lines to create
higher-purity b cell clusters based on b cell markers such as in-
sulin, NKX6.1, or CD177.13,28,29 Purifying methods enabled the
study of diabetes-relevant b cells for disease modeling in vitro
and transplanting b cells in vivo.
Innovative refinements to remove off target cells during the EP
stage used latrunculin A, an actin cytoskeleton modulator, to
enrich the endocrine population.12,17 This protocol provided an
opportunity to perform the SC-islet differentiation in planar in 6
stages, reducing technical expertise and costly equipment for
three-dimensional (3D) culture. In addition, the removal of
function-inhibiting small molecules and reaggregation in the final
differentiation stage enhanced the function of SC-islets and
showcased the rapid reversal of diabetes in rodent models
with patient SC-b cells.13,14 The improved protocols required
minimal optimization of multiple patient iPSC lines for successful
differentiations. The SC-islets contained almost pure endocrine
cell populations.12We and our colleagues can now readily inves-
tigate SC-islets from patients with diabetes.
DISEASE MODELING WITH iPSCs FROM PATIENTS
WITH DIABETES
SC-islets from patients with diabetes are critical to gain a better
understanding of the disease and its progression. Thus, iPSCs
have been reprogrammed from patients with T1D, T2D,
MODY, CFRD, WS, and NeoD (Figure 1; Tables 1 and 2). Typi-
cally, the Yamanaka factors (OCT4, KLF4, SOX2, c-MYC) were
Figure 1. Applications of SC-islets from patients with diabetes
Patient tissue biopsies can be reprogrammed into induced pluripotent stem cells (iPSCs) and differentiated into stem cell-derived islets (SC-islets) that contain b
(SC-b) cells. These SC-islets have applications in disease modeling, gene editing, and cell therapy in animal models. They also provide a source for autologous
cell replacement therapy for patients with diabetes. DE, definitive endoderm; EP, endocrine progenitor; PGT, primitive gut tube; PP, pancreatic progenitor.




used to reprogram the somatic cells through either retrovirus,
Sendai virus, or episomal reprogramming.30,31 Alternatively,
Sui et al.24 used somatic cell NT to generate T1D NT-ESCs
from skin fibroblasts. Studies differentiated patient iPSCs into
SC-b cells and progenitors, and investigated cell maturation, dif-
ferentiation efficiencies, and insulin secretion function. When dif-
ferences were found, they typically occurred after pancreatic cell
fate was designated. The cells were commonly compared to
either nondiabetic or gene-edited isogenic controls. Genetic en-
gineering is used to reverse these effects and correct the known
diabetes, causing mutations.
T1D and T2D are themost common forms of diabetesmellitus,
constituting 10% and 90% of patients with diabetes, respec-
tively.3 Understanding the pathophysiology of these diseases
is complex due to risk factors, including epigenetics, environ-
ment, and lifestyle. Many rodent models of T1D and T2D exist;
however, there are several physiologic differences between ro-
dents and humans, specifically in the islets.44,45 Therefore, we
and others used stem cell technology to create iPS cells from hu-
man patients to model T1D and T2D and gain a better under-
standing of disease pathogenesis (Table 1). Early studies used
PDX1+NKX6-1+ PPs, which give rise to all pancreatic cell fates.
T1D iPSC-b cells functioned and had differentiation efficiencies
similar to ND iPSC-b cells,36 which is consistent with previous re-
ports comparing T1D and NDSC-PPs.37 Under further investiga-
tion, in vitromodeling systems revealed that T1D patient-derived
endocrine cells respond to stress36 and react to autologous
immune cells in a cell-type-specific manner, providing a better
understanding of T1D pathogenesis.32 There is no literature
investigating SC-islets from patients with T2D; however, T2D
iPSCs are available.30 There are multiple studies using patient
iPSCs with T2D-risk variants including SLC30A8,34 TRMT10A,27
and PDX1.33 To further study T2D, next-generation sequencing
(NGS) identified gene expression differences in T2D primary hu-
man islets compared to healthy controls.46,47 Xin et al.48 reported
differentially expressed genes found in the main endocrine islet
cell types. Specifically, in b cells, PAXBP-1, GLS2, and
FXYD23 are upregulated and G6PC2, GLRA1, and IGFBPL1
are downregulated.
CFRD and MD are rarer forms of diabetes that limit the avail-
ability of primary samples. Thus, patient iPSCs are critical for un-
covering disease pathogenesis and therapeutic development.
Pancreatic ductal epithelial cells were derived from iPSCs with
a CF genetic background, creating a drug screening platform
in vitro.49 MD is caused by a single gene mutation that occurs
in roughly 2% of patients who are diagnosed with diabetes mel-
litus (reviewed by Harris et al.50). Patient iPSCs from MODY,
NeoD, and WS backgrounds have allowed for human MD
modeling. Recent publications investigated mutations in PDX1,
GLIS3, HNF1A, HNF1B, GCK, INS, GATA6, SUR1, and WFS1,
which are each related to a form of MD (Table 2). Genetic engi-
neering tools were commonly applied to correct the known
mutation in an isogenic cell line, which often led to a healthy
phenotype (Table 2).15–17,33,34,35,38,39,42 Diabetic SC derivatives
were typically less efficient in generating SC-islets, SC-b cells,
and SC-PPs. This occurred when evaluating mutations in
GATA6,40 WFS1,17,42 and PDX133 (Table 2). However, the
SUR1 mutation caused the inactivation of the KATP channel, re-
sulting in congenital hyperinsulinism (CHI) and eventually
MODY, producing an increased number of SC-b-like cells with
greater function.38 Transplantation was commonly performed
to observe cell maturation in vivo and examine whether cells
could either reverse preexisting diabetes or prevent diabetes
induction in mice (Table 2). In summary, human iPSC differentia-
tion protocols enable the study of diabetic b cells and progeni-
tors in vitro.
INSIGHTS IN STEM CELL-DERIVED ISLETS FROM NGS
OF iPSCs
Several iPSC studies used NGS strategies15,17,33 and microar-
rays36,37,40,51 to study differentially expressed genes in specific
islet cell types, such as a and b cells. Balboa et al.15 andMaxwell
et al.17 used single-cell NGS, and both studies observed in-
creases in b cell genes for gene-edited SC-b-like and SC-b cells.
Wang et al.33 identified downregulated PDX1-bound genes that
reduce differentiation efficiency, including MNX1, CES1, and
MEG3. Millman et al.36 identified TAP1 as the largest
Table 1. Summary of T1D and T2D patient iPSC cell line studies for diabetes-in-a-dish
Study reference Diabetic state Cell type generated In vivo transplantation Additional notes
Leite et al. (2020)32 T1D SC-b and SC-a cells no isogenic co-culture
with immune cells
Wang et al. (2019)33 T2D b-like cells no microarray, RNA-seq, and
ChIP-seq data from PPs
Dwivedi et al. (2019)34 T2D b-like cells – RNA-seq
Sui et al. (2018)24 T1D NT-iPSC-b cells yes, prevent
diabetes onset
NT patient SCs
Cosentino et al. (2018)27 T2D b-like cells no –
Amin et al. (2018)35 T1D, T2D SC-b cells yes, study in vivo cells chemical screen, RNA-seq
of sorted b sorted cells
Millman et al. (2016)36 T1D SC-b cells yes, prevent
diabetes onset
microarray data
Thatava et al. (2013)37 T1D Pancreatic
islet-like cells
– microarray data of iPSCs




differentially expressed gene in T1D SC-b cells compared to
healthy patients. Recently, Augsornworawat et al.26 evaluated
the transcriptome of transplanted SC-islets with single-cell
RNA sequencing from both ESCs and iPSCs to show the strong
resemblance of in vivo SC-islets and primary human islets. A
maturation list for b and a cells was curated from the sequencing
data, providing a resource of targets for b cell maturation
in vitro.26 NGS of primary human islets and SC-islets was previ-
ously reviewed and highlighted key findings for the differences
between diabetic and nondiabetic human islets, as well as
important islet cell type-defining gene signatures.52 Of note,
Muraro et al.53 and Segerstolpe et al.46 characterized human
islet samples fromND and T2D patients. Krentz et al.54 and Hrva-
tin et al.51 compared progenitor cell types to human islets. Lastly,
Veres et al.25 profiled the various stages of differentiation to yield
a potential cell sortingmechanismwith CD49a and identified SC-
EC cells. Xin et al.48 detailed the unfolded protein response in pri-
mary b cells frommultiple donors. These studies used innovative




(1) SC-islets and progenitor derivatives are used to model
diabetes-in-a-dish. Endoplasmic reticulum (ER) stress ex-
periments are commonly applied to ND and diabetic SC-
islets to represent diabetes in vitro.55 In all forms of dia-
betes, ER stress is found in b cells, causing dysfunction
and eventual unfolded protein response (UPR)-mediated
cell death.56 Balboa et al.,15 Shang et al.,42 and Maxwell
et al.17 studied SC-b cells and progenitors from patients





























MODY3 HNF1A b-like cells yes, CRISPR/Cas9 to
introduce HET and
homozygous KO mutations








































































MODY1 HNF4A – – – –
MODY1 HNF4A – – – –
MODY2 GCK – – – –
MODY3 HNF1A – – – –
MODY5 HNF1B – – – –
MODY5 HNF1B – – – –
MODY8 CEL – – – –




with mutations linked to diabetes and known to cause ER
stress. The results revealed a combination of increased
protein and gene expression of ER stress markers,
dysfunctional insulin processing, and reduced insulin
secretion in response to glucose. Shang et al.42 and
Maxwell et al.17 also showed dilated ER with electron mi-
croscopy, indicating ER stress. Balboa et al.15 and
Maxwell et al.17 used NGS to identify increased ER stress
(ATF6, BiP/HSPA5), apoptosis (CHOP, CASP3), and
oxidative stress transcripts (TXNiP). SC-b cells with
greater maturation compared to progenitors influenced
ER stress and study results. As portrayed when
comparing WS studies, SC-b cells17 were more mature
than insulin-producing cells,42 indicated by the attain-
ment of b cell markers and functional insulin secretion in
response to glucose. Specifically, for WS studies, C-Pep-
tide+ insulin-producing cell yields were not reduced with a
WFS1 mutation; however, SC-b cells had lower yields
when comparing the unedited and corrected iPSC differ-
entiations. Greater insulin production supported higher
functional capacity, and in return, increased ER stress
due to increased insulin production and protein folding.
The inability to handle elevated protein folding activated
the unfolding protein response at a basal level and likely
influenced differentiation from EPs to SC-b cells. There
are few articles available examining ER stress in human
islets48,57; therefore, human SC-islets are a critical
resource to understand diabetes-in-a-dish.
(2) Transgenic cell lines are generated through editing tech-
nologies that insert and express foreign DNA. For dia-
betes research, transgenic stem cells were created using
biotechnology to either study diabetes through the inser-
tion of a known diabetes-causing variant or monitor differ-
entiation with a reporter cell line. This technology
advancement was critical to study known variants associ-
ated with T1D and T2D. Amin et al.35 used a GLIS3
mutation associated with T1D, T2D, and NeoD to
generate SC-PP2 and SC-PP2-b cells. With the mutation,
they observed increased cell death and impaired differen-
tiation compared to isogenic controls, developing a drug
screening platform. Shang et al.42 transfected WT WFS1
lentivirus in their patient iPS-derived insulin-producing
cells to model WS in vitro. Dwivedi et al.34 inserted a
ZnT8 loss-of-function (LoF) allele, expected to protect
against T2D, using CRISPR/Cas9 in patient iPSCs and
found increased glucose responsiveness, making ZnT8
a promising target for increased insulin secretion as a
T2D treatment. Transgenic stem cell lines were also
used to study neurologic, epidermal, and cardiomyocyte
disorders.
(3) Microfluidic devices are used to mimic the in vivo
pancreas and islet microenvironment. Engineered de-
vices perturbed islet function by enhancing insulin
sensing, monitoring islet hormone secretion in response
to glucose, and quantifying pulsatile insulin release.Misun
et al.58 generated a device to monitor dynamic insulin
secretion of a single human islet. Lenguito et al.59 com-
bined convective fluidic devices and computational
modeling of glucose-stimulated insulin secretion (GSIS)
to develop a competitive alternative to commercially
available perifusion systemswith the opportunity to image
cells while in the machine. Jun et al.60 and Sankar et al.61
developed a dynamic culture system as an alternative to
typical static culture by integrating interstitial flow to bet-
ter mimic in vivo islet conditions in vitro. Glieberman
et al.62 designed a microfluidic device incorporating the
native islet microenvironment by delivering pulsatile insu-
lin through arteriole and capillary channels on a chip. This
system also continuously monitored insulin release,
quantified with fluorescence anisotropy. Future protocols
may benefit from differentiating PSCs in these engineered
culture devices, such as the integrated platform devel-
oped by Ishahak et al.63 that incorporated continuous
perfusion culture with the ability to monitor functional
maturation. These newly developed devices are compet-
itive platforms for drug screening and studying dynamic
insulin secretion in vitro.
(4) Sorting SC-b cells and progenitors are helpful in studying
specific cell types of interest and removing off target cell
types from differentiation protocols. Several studies used
NKX6.1GFP/w and INSGFP/w stem cell lines to enhance SC-
b cell yields.16,24,28,64 Mahaddalkar et al.65 identified ante-
rior DE markers CD177 and CD275 to specify pancreatic
and liver fates, respectively Thus, they sorted for
CD177+CD275 after DE was defined in the first stage
of SC-islet differentiation, improving the percentage of
INS+NKX6.1+ b-like cells at stage 7. To enrich functional
cells, Li et al.66 sorted human b-like cells for CD9, a cell-
surface marker found in immature human b cells, to nega-
tively enrich glucose-responsive cells. In addition, Veres
et al.25 recently identified CD49a/ITGA1 as a surface
marker for b cells in SC-islet clusters, thereby increasing
the insulin secretion of individual islets. Sorting strategies
are beneficial to study b cells for disease-in-a-dish
modeling of diabetes.
INSIGHTS IN DISEASE MECHANISM THROUGH GENE
EDITING
Editing of genes important for b cell differentiation is commonly
performed in the SC-b cell field to determine the effect on b cell
insulin secretion. The impact of PDX1, MAFA, and NEUROG3
have been extensively studied in SC-b cells (review by Zhu
et al.67). Gene editing has also been proposed for cell therapy
efforts in both correction of diabetes-causing mutations and
resistance to immune rejection. We and other colleagues used
CRISPR/Cas9 and lentiviral transduction to correct known dia-
betes-causing mutations in patient iPSCs. Maxwell et al.17
and Ma et al.16 used gene correction to reverse and prevent dia-
betes in mice, respectively. These results are very promising for
the potential of an autologous cell therapy. Lithovius et al.38 cor-
rected the SUR1 mutant KATP activator and identified a role for
the KATP channel in development by revealing increased insulin
secretion and proliferation of the mutant compared to the
isogenic gene-corrected SC-b-like cells. Enhanced function
was expected as patients with CHI, and eventually MODY, are




unable to initiate membrane depolarization and continually
secrete insulin.38 Eichstadt et al.68 used gene-corrected autolo-
gous cell therapy in a Phase I/IIa clinical trial for recessive
dystrophic epidermolyis bullosa and observed no adverse ef-
fects. Rı́o et al.69 published results from a Phase I/II clinical trial
of gene-corrected hematopoietic gene therapy for patients with
Fanconi anemia and also detected no immune rejection effects.
However, there remains concern that gene editing of autolo-
gous cells may cause immune rejection due to the autoimmune
reactive nature of diabetes. Therefore, the current efforts inves-
tigating immune rejection resistance in allogeneic cell therapy
may also be needed to a lesser extent for autologous cell ther-
apy. Genome engineering to address immune intervention was
previously reviewed.70 For SC-b cell therapy, key targets for the
genome engineering of diabetes cell therapy included human
leukocyte antigen (HLA) modification to expand SC-islet utility
and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4)
and programmed death-1/programmed death ligand-1 (PD-1/
PD-L1) adjustment to target T cell immune rejection upon trans-
plantation.71,72 Alternate iPSC-derived engineered cell types
(endothelial, smooth muscle, cardiomyocytes) described by
Deuse et al.73 used major histocompatibility complex (MHC)-
mismatched allogeneic sources to inactivate the MHC class I
and II genes and overexpress CD47 with CRISPR/Cas9 to suc-
cessfully evade immunosuppression in recipients. These ad-
vances in SC-b cell and alternate cell genetic engineering aim
to address an unmet need in the autologous and allogeneic
stem cell therapy field.
INSIGHTS ON IN VIVO CELL THERAPY WITH ANIMAL
MODELS
To develop an adequate cell therapy, in vivo testing is needed in
animal models for therapeutic validation. Our group and col-
leagues have established several studies confirming the use of
SC-islets, SC-b cells, and PPs for cell therapy in rodent models.
Validation methods included prevention of diabetes16,24,42,74,75
and diabetes reversal10,11,13,14,17 by transplanting cells in the
kidney capsule before or after diabetes induction, respectively.
Streptozotocin and alloxan induced diabetes in mouse and rat
models. Nephrectomies were also commonly performed to
confirm that the transplanted cells were the source of euglyce-
mia in kidney capsule transplants.9,12,17,24,75,76 Several groups
confirmed the maturation of SC-islets, SC-b cells, and PPs
post-transplantation with immunostaining. Transplantation sites
ranged from portal vein, intramuscular, and subcutaneous to
kidney capsule.12,16,24,75 The impact on pregnancy and sex
between mouse recipients revealed no differences between
male and female mice.75,77 In vivo models were used to test
encapsulation devices with stem cell-derived b-like cells and
progenitors.75,78–81 Transplantation was typically assessed in
immunocompromised mice due to immune rejection of SC-is-
lets; however, Yoshihara et al.72 successfully transplanted and
maintained glucose homeostasis in diabetic immunocompetent
mice for 50 days, with their human islet-like organoids geneti-
cally engineered to overexpress PD-L1. These combined efforts
for in vivo testing are encouraging that a diabetes cell therapy will
soon be produced.
PERSONALIZED CELL REPLACEMENT THERAPY
The standard care of treatment for patients with T1D is exoge-
nous insulin. Risks and complications involved with this treat-
ment include hypoglycemia, swelling and infection at injection
site, and weight gain. In addition, long-term exposure may in-
crease cardiovascular complications, stroke risk, and kidney
damage, due to uncontrolled hyperglycemic and hypoglycemic
events.82 Experimental treatment methods currently in practice
include pancreas and cadaveric islet transplantation.83–85 These
methods were only used when a patient was unresponsive to
standard treatment or kidney damage was present and the pa-
tient concurrently underwent kidney transplantation surgery.
Cadaveric islet transplantations have limited donor availability
and require multiple donors, resulting in donor-to-donor
variation. Clinical trials are also under way byViaCyte using allo-
geneic stem cell-derived PPs and an encapsulation device
(NCT02239354 and NCT03163511) and planned by Vertex Phar-
maceuticals using allogeneic SC-islets (NCT04786262). The
transplantation of allogeneic cells and organs requires the recip-
ient to be taking immunosuppressive drugs, which can be prob-
lematic for patients with T1D. SC-islets overcome several of
these limitations, providing an unlimited cell source with robust
function for use as a cell therapy. Autologous diabetes cell ther-
apy ismade possible with patient iPSC-islets, which contain their
missing insulin-secreting b cells, and has the potential to remove
the need for immunosuppressive drugs post-transplant. How-
ever, there is a financial concern regarding autologous cell ther-
apies for a wide range of diseases. Once cell therapy is estab-
lished as a safe and viable treatment for disease, measures to
reduce costs will be used, allowing for mass cell product
manufacturing. Protocol updates will enable the generation of
large cell batches, enabling the cryopreservation of functional
SC-b cells.75 An additional concern is de novomutations in mito-
chondrial DNA occurring in autologous iPSCs and leading to the
production of neoantigens, dependent on MHC genotype.86
With advances in stem cell technology, diabetes cell therapy
can be used in a wider patient population, including insulin-
independent patients with T1D and T2D and those undergoing
a pancreatectomy.
FUTURE OUTLOOK
In general, there are technical difficulties and financial concerns
related to iPSC therapy. To reduce the financial burden, biobanks
of genome-stable iPSCs capable ofmatching themajority of HLA
types87 and rarer blood types88 are being explored. This format
would create more personalized medicine than allogeneic while
also reduce the immunogenicity through HLA matching.87 Bio-
banks would also ease the technical and costly difficulties of
personalizedmedicine by creating banks of HLA-matched differ-
entiated cell types using mass production. Genomic instability is
an additional obstacle in iPSC therapy clinical translation. When
reprogramming somatic cells to iPSCs, chromosomal aberra-
tions or mutations often occur.89 Furthermore, tumor formation
remains a concern.While diabetes stemcell replacement therapy
has several established protocols that have little to no detectable
teratoma-forming cells,12 many organs and differentiated cell




types necessary to address other diseases remain preliminary
and will require several additional iterations before clinical trans-
lation can occur. However, genetic engineering of suicide genes
to destroy transplanted cells upon tumor formation is being
investigated.90 After these obstacles are overcome and stem
cell therapy is available in the clinical setting, the quality of life
will be greatly increased for patients worldwide.
SC-islets are a promising renewable cell source for diabetes
cell therapy that can be produced with recent differentiation
protocols.12,13,25 While advances in SC-islet differentiation pro-
tocols are encouraging, a universal differentiation protocol
adaptable to all iPSC lines would better facilitate autologous
cell therapy. This would eliminate the costly and time-consuming
optimization and difficulties that are often encountered with new
cell lines. Genetic engineering tools could aid in advancing autol-
ogous diabetes cell therapy research. These tools could identify
iPSC or early-stage markers that define suitability for an efficient
SC-islet differentiation65 or genes to overexpress in iPSCs to
initiate or improve differentiation.91 In addition, reporters to
enable robust readouts of function and maturation after cell
fate specification would help both cell therapy development
and drug screening applications.92–94 Ideally, SC-islets would
be indistinguishable from primary islets for transplantation, spe-
cifically in terms of glucose-stimulated insulin secretion, but
further protocol improvements are needed to achieve this.
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Kroon, E.J., and Pipeleers, D.G. (2018). Functional beta cell mass from de-
vice-encapsulated hESC-derived pancreatic endoderm achieving meta-
bolic control. Stem Cell Reports 10, 739–750.
80. Chang, R., Faleo, G., Russ, H.A., Parent, A.V., Elledge, S.K., Bernards,
D.A., Allen, J.L., Villanueva, K., Hebrok, M., Tang, Q., and Desai, T.A.
(2017). Nanoporous immunoprotective device for stem-cell-derived
b-cell replacement therapy. ACS Nano 11, 7747–7757.
81. Desai, T., and Shea, L.D. (2017). Advances in islet encapsulation technol-
ogies. Nat. Rev. Drug Discov. 16, 338–350.
82. Nathan, D.M. (1993). Long-term complications of diabetes mellitus.
N. Engl. J. Med. 328, 1676–1685.
83. Scharp, D.W., Lacy, P.E., Santiago, J.V., McCullough, C.S., Weide, L.G.,
Falqui, L., Marchetti, P., Gingerich, R.L., Jaffe, A.S., Cryer, P.E., et al.
(1990). Insulin independence after islet transplantation into type I diabetic
patient. Diabetes 39, 515–518.
84. Shapiro, A.M., Ricordi, C., Hering, B.J., Auchincloss, H., Lindblad, R.,
Robertson, R.P., Secchi, A., Brendel, M.D., Berney, T., Brennan, D.C.,
et al. (2006). International trial of the Edmonton protocol for islet transplan-
tation. N. Engl. J. Med. 355, 1318–1330.
85. Shapiro, A.M.J., Lakey, J.R.T., Ryan, E.A., Korbutt, G.S., Toth, E., War-
nock, G.L., Kneteman, N.M., and Rajotte, R.V. (2000). Islet transplantation
in seven patients with type 1 diabetes mellitus using a glucocorticoid-free
immunosuppressive regimen. N. Engl. J. Med. 343, 230–238.
86. Deuse, T., Hu, X., Agbor-Enoh, S., Koch, M., Spitzer, M.H., Gravina, A.,
Alawi, M., Marishta, A., Peters, B., Kosaloglu-Yalcin, Z., et al. (2019). De
novo mutations in mitochondrial DNA of iPSCs produce immunogenic
neoepitopes in mice and humans. Nat. Biotechnol. 37, 1137–1144.
87. de Rham, C., and Villard, J. (2014). Potential and limitation of HLA-based
banking of human pluripotent stem cells for cell therapy. J. Immunol. Res.
2014, 518135.
88. Park, Y.J., Jeon, S.H., Kim, H.K., Suh, E.J., Choi, S.J., Kim, S., and Kim,
H.O. (2020). Human induced pluripotent stem cell line banking for the pro-
duction of rare blood type erythrocytes. J. Transl. Med. 18, 236.




89. Turinetto, V., Orlando, L., and Giachino, C. (2017). Induced Pluripotent
StemCells: Advances in theQuest for Genetic Stability during Reprogram-
ming Process. Int. J. Mol. Sci. 18, E1952.
90. Penney, J., Ralvenius, W.T., and Tsai, L.H. (2020). Modeling Alzheimer’s
disease with iPSC-derived brain cells. Mol. Psychiatry 25, 148–167.
91. Ng, A.H.M., Khoshakhlagh, P., Rojo Arias, J.E., Pasquini, G., Wang, K.,
Swiersy, A., Shipman, S.L., Appleton, E., Kiaee, K., Kohman, R.E., et al.
(2020). A comprehensive library of human transcription factors for cell
fate engineering. Nat. Biotechnol. https://doi.org/10.1038/s41587-020-
0742-6.
92. Cardenas-Diaz, F.L., Leavens, K.F., Kishore, S., Osorio-Quintero, C.,
Chen, Y.J., Stanger, B.Z., Wang, P., French, D., and Gadue, P. (2020). A
Dual Reporter EndoC-bH1 Human b-Cell Line for Efficient Quantification
of Calcium Flux and Insulin Secretion. Endocrinology 161, bqaa005.
93. Kracht, M.J.L., de Koning, E.J.P., Hoeben, R.C., Roep, B.O., and Zaldum-
bide, A. (2018). Bioluminescent reporter assay for monitoring ER stress in
human beta cells. Sci. Rep. 8, 17738.
94. Burns, S.M., Vetere, A., Walpita, D., Dancı́k, V., Khodier, C., Perez, J.,
Clemons, P.A., Wagner, B.K., and Altshuler, D. (2015). High-throughput
luminescent reporter of insulin secretion for discovering regulators of
pancreatic Beta-cell function. Cell Metab. 21, 126–137.
10 Cell Reports Medicine 2, 100238, April 20, 2021
Review
ll
OPEN ACCESS
